普罗吉尼生育健康
PGNY
26.86
-0.60
-2.17%
普罗吉尼生育健康
US · PGNY
#2809 按市值排名
上市于 2019
26.86
-0.60
-2.17%
实时 - 追踪5344个代码 - 心跳于3秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了0.3个百分点。
机构持股
- 机构持股比例
- 110.57% -0.29pp
- 机构数量
- 381 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund81.02%
Hedge Fund11.14%
VC/PE Fund6.61%
Insurance Company3.91%
Public Company2.78%
Private Company2.77%
Government Pension Fund1.87%
Individual/Insider1.81%
Sovereign Wealth Fund0.20%
主要股东 截至 2026-06-30
BlackRock
15.12% · 11.60M 股
FMR
9.13% · 7.00M 股
Kleiner Perkins Caufield & Byers LLC
6.61% · 5.07M 股
Vanguard Portfolio Management, LLC
6.54% · 5.02M 股
Vanguard Capital Management, LLC
4.86% · 3.73M 股
State Street Global Advisors
3.94% · 3.02M 股
Columbia Management Investment Advisers, LLC
3.60% · 2.76M 股
Fort Washington Investment Advisors, Inc.
3.32% · 2.55M 股
Geode Capital Management, LLC
2.57% · 1.97M 股
Citadel Advisors LLC
2.33% · 1.79M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 17次买入 · 33次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Peter Anevski | Chief Executive Officer | 0.76% |
| Norman Payson | Independent Director | 0.59% |
| David Schlanger | Executive Chairperson | 0.31% |
| Allison Swartz | General Counsel | 0.03% |
| Jeffrey Park | Independent Director | 0.03% |
| Kevin Gordon | Independent Director | 0.02% |
| Cheryl Scott | Independent Director | 0.02% |
| Roger Holstein | Independent Director | 0.02% |
| Lloyd Dean | Independent Director | 0.02% |
| Geoffrey Clapp | Chief Product Officer | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-22 | Allison Swartz | General Counsel | Automatic Disposition | -3,903 | $26.10 |
| 2026-09-16 | Geoffrey Clapp | Chief Product Officer | Sale to Issuer | -819 | $27.38 |
| 2026-09-09 | Kevin Gordon | Independent Director | Derivative Exercise and Sale | -22,000 | $13.00–27.24 |
| 2026-09-03 | Mark Livingston | Chief Financial Officer | Sale to Issuer | -479 | $26.61 |
| 2026-09-03 | Allison Swartz | General Counsel | Sale to Issuer | -1,307 | $26.29–26.61 |
| 2026-09-02 | Peter Anevski | Chief Executive Officer | Sale to Issuer | -5,361 | $26.29 |
| 2026-09-02 | Mark Livingston | Chief Financial Officer | Sale to Issuer | -1,756 | $25.66–26.29 |
| 2026-08-27 | Allison Swartz | General Counsel | Sale to Issuer | -1,352 | $25.86 |
| 2026-07-13 | Melissa Cummings | Chief Operating Officer | Sale to Issuer | -1,193 | $31.98 |
| 2026-07-13 | Melissa Cummings | Chief Operating Officer | Automatic Disposition | -2,244 | $31.60 |
| 2026-06-16 | Geoffrey Clapp | Chief Product Officer | Sale to Issuer | -819 | $26.60 |
| 2026-06-03 | Mark Livingston | Chief Financial Officer | Sale to Issuer | -1,421 | $24.99–25.12 |
| 2026-06-03 | Mark Livingston | Chief Financial Officer | Automatic Disposition | -2,517 | $25.50 |
| 2026-06-03 | Allison Swartz | General Counsel | Sale to Issuer | -1,015 | $24.99–25.12 |
| 2026-06-03 | Allison Swartz | General Counsel | Automatic Disposition | -1,798 | $25.02–25.08 |
| 2026-06-03 | Allison Swartz | General Counsel | Intent to Sell (Form 144) | -599 | $25.08 |
| 2026-06-02 | Peter Anevski | Chief Executive Officer | Sale to Issuer | -5,361 | $25.12 |
| 2026-06-02 | Allison Swartz | General Counsel | Intent to Sell (Form 144) | -1,199 | $25.02 |
| 2026-06-01 | Geoffrey Clapp | Chief Product Officer | Derivative Exercise and Sale | -12,909 | $20.91–25.58 |
| 2026-06-01 | Mark Livingston | Chief Financial Officer | Sale to Issuer | -158 | $26.20 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
普罗吉尼生育健康 讨论区 0 条评论